Immune reactivity to HER-2/neu protein for diagnosis and...

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S326000, C530S300000, C530S350000, C530S403000, C530S402000, C424S184100, C424S185100, C424S277100, C514S002600, C514S014800, C514S015800, C930S010000

Reexamination Certificate

active

10647005

ABSTRACT:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2
eu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2
eu protein, or detection of immunocomplexes formed between the HER-2
eu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2
eu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 5958784 (1999-09-01), Benner
patent: 5985553 (1999-11-01), King et al.
patent: 6514942 (2003-02-01), Ioannides et al.
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
Disis, M.L. et al., “Immunity to the HER-2/Neu Oncogenic Protein”,Ciba Foundation Symposium,Amsterdam, NL, 187:198-211, 1994.
Disis, M.L. et al., “Immunization to Oncogenic HER-2
eu Protein With Peptide Based Vaccines”,Proc. Amer. Assn. for Cancer Research 36:251 (abstract 1498) Mar. 1995.
Alper et al., “The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3,”Cell Growth&Differentiation 1:591-599, 1990.
Bargmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,”Nature319:226-230, 1986.
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185({circumflex over ())}{circumflex over (})}HER2) Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer,”Journal of Clinical Oncology 14(3): 737-744, 1996.
Ben-Mahrez et al., “Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients,”Int. J. Cancer 46: 35-38, 1990.
Bishop and Orosz, “Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells,”Transplantation 47(4): 671-677, 1989.
Bodmer, W., “T-Cell Immune Respones to Cancer—A New Look,”Human Immunology 30:259-261, 1991.
Bowen-Pope et al., “Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents,”Proc. Natl. Acad. Sci. USA 81:2396-2400, 1984.
Brooks et al., “Human lymphocyte markers defined by antibodies derived from somatic cell hybrids,”Clin. Exp. Immunol. 39: 477-485, 1980.
Brown et al., “Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies,”Journal of Biological Chemistry 255(11): 4980-4983, 1980.
Burnette et al., “Western Blotting: Electropheretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody Radioiodinated Protein A,”Analytical Biochemistry 112: 195-203, 1981.
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,”Science 230:1132-1139, 1985.
Dhut et al, “BCR-ABL and BCR Proteins: Biochemical Characterization and Localization,”Leukemia 4(11): 745-750, 1990.
Disis et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients With Breast Cancer,”Cancer Res. 54: 16-20, 1994.
Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,”Nature 351: 290-296, 1991.
Feller and de la Cruz, “Identifying antigenic T-Cell sites,”Nature 349: 720-721, 1991.
Fisk et al., “Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro,”Cellular Immunology 157:415-427, 1994.
Flanagan and Leder, “neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation,”Proc. Natl. Acad. Sci. USA 85: 8057-8061, 1998.
Igelhart et al., “Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer,”Cancer Research 50:6701-6707, 1990.
Ioannides et al., “Antigens Rocognized by T cells in Ovarian Cancer,” in Abstracts of the Fourth International Conference of Anticancer Research, Oct. 21-25, 1992, Rethymnon, Crete, Greece, p. 1870.
Ioannides et al., “CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2
eu Gene Product,”FASEB Journal 6: A1404, Abstract No. 2711, 1992.
Ioannides et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,”Cell. Immunol. 151: 225-234, 1993.
Ionnides et al., “Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones,”Scand. J. Immunol. 37: 413-424, 1993.
Ioannides et al., “T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy,”Molecular Carcinogenesis 6:77-82, 1992.
Ioannides, Abstracts Fourth International Conference of Anticancer Research Oct. 21-25, 1992, p. 1870.
Ioannides, “Antigens and vaccines of female genital cancers (Meeting abstract),” Cancerlit Database Abstract No. ICDB/93690682, 1992.
Ioannides, et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,”Cell Immunol. 151:225-234, 1993.
Ioannides, Society for Biological Therapy 1992 Annual Meeting, p. 27 Oct. 29-Nov. 1, 1992.
Kallioniemi et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,”Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., “c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry,”Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,”Nature 227: 680-685, 1970.
Leitzel et al., “Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients,”Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lichtenstein et al., “Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2
eu Oncogene-Expressing and Nonexpressin Target Cells to Lymphocyte-Mediated Lysis,”Cellular Immunology 141: 219-232, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer,”Advances in Oncology 8(3): 26-28, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer”,Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, “The neu (c-erbB-2) Oncogene,”Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., “Prediction of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence,”Journal of Immunology 138(7): 2213-2229, 1987.
McGlynn et al., “Large-scale purfication and

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immune reactivity to HER-2/neu protein for diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immune reactivity to HER-2/neu protein for diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune reactivity to HER-2/neu protein for diagnosis and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3733410

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.